第15届Rivkin中心双年会卵巢癌研究研讨会
Kenneth P Nephew1, Ronny Drapkin2, Jackie Lang3
1Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.
Gynecologic oncology
|November 6, 2025
概括
第15届两年一度的卵巢癌研究研讨会强调了卵巢癌生物学,免疫疗法和新兴疗法方面的进展. 它强调了患者的观点,并解决了卵巢癌研究中的医疗保健差异.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症研究 癌症研究
- 翻译科学 翻译科学
背景情况:
- 第15届两年一度的卵巢癌研究研讨会将于2024年9月召开.
- 这一重要活动由Rivkin卵巢癌研究中心和美国癌症研究协会联合举办.
- 座谈会的重点是卵巢癌研究的关键领域.
研究的目的:
- 介绍和讨论最近的卵巢癌研究进展.
- 促进患者和研究人员之间的合作.
- 为应对卵巢癌预防,检测和治疗方面的挑战.
主要方法:
- 口头和海报演讲涵盖了五个主要研究领域.
- 一个患者倡导小组讨论.
- 讨论新型免疫疗法和新兴疗法.
主要成果:
- 突出了卵巢癌生物学上的新进展.
- 展示了新型免疫疗法和新兴治疗方法的进展.
- 强调了以患者为中心的研究和医疗保健公平的重要性.
结论:
- 座谈会强调了在卵巢癌研究中进行跨学科合作的必要性.
- 了解卵巢癌生物学和开发新治疗方法的进展正在取得进展.
- 解决医疗保健差异对于改善患者的治疗结果至关重要.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


